HIV/AIDS
Conditions
Brief summary
This study will use community-informed advertisements and messages through electronic methods to recruit and retain a large (N=3,200), diverse national sample of high-risk young men who have sex with men (YMSM) and non-binary individuals that are assigned male sex at birth, 16-29 years of age to determine the efficacy of the MyPEEPS Mobile intervention on reduced incident HIV infections in comparison to a standard of care condition and to examine the degree to which reduced incident HIV infections occurs in the context of potential multilevel moderators and conceptual mediators. This is key to advancing HIV prevention among HIV-negative US persons at extremely high-risk for HIV seroconversion.
Detailed description
In direct response to RFA-AI-21-018, Limited Interaction Targeted Epidemiology (LITE-2): To Advance HIV Prevention (UG3/UH3 Clinical Trial Optional), we proposed to harness innovative electronic methods to conduct a large, rigorous national study collecting and contextualizing epidemiological HIV incidence data in Young Men who have Sex with Men (YMSM) and testing the efficacy of MyPEEPS Mobile, an evidence-based, digitally delivered mHealth sexual risk reduction intervention on HIV incidence. We proposed to establish a large national cohort of 3,200 racially and ethnically diverse YMSM 16-29 years old, the age YMSM are most susceptible to HIV acquisition to identify theoretically-driven correlates of HIV seroconversion among a key population experiencing a disproportionate number of new HIV diagnoses. Randomized controlled trials (RCTs) are considered the gold standard for estimating treatment efficacy because randomization mitigates risk of bias by balancing measured and unmeasured confounders across treatment groups. However, RCTs are costly, time-consuming, and can be challenging to conduct in certain context. We are therefore integrating the robust epidemiological data that we collected during the UG3 phase into the clinical trial design. That integration is a potentially appealing way to generate an external comparator cohort to increase the power of our RCT to estimate the effect of MyPEEPS Mobile on HIV incidence.
Interventions
BEHAVIORALMyPEEPS Mobile
An evidence-based, digitally delivered mHealth sexual risk reduction intervention on HIV incidence.
Sponsors
Columbia University
Ann & Robert H Lurie Children's Hospital of Chicago
Northwestern University
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
MALE
Age
16 Years to 29 Years
Healthy volunteers
Yes
Inclusion criteria
* Be between 16-29 years of age; * Sex assigned at birth is male and identify gender as male or non-binary; * Understand and read English; * Live within US and its territories; * Own or have access to a smartphone; * Self-report anal sex with someone who has a penis in the last 12 months; and * Be HIV-negative or status unknown
Exclusion criteria
* Individuals who identify as transgender
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| HIV Incidence | Baseline, 6 month follow up, 12 month follow up. | OraQuick In-Home HIV Tests will be shipped to participants at baseline, 6 and 12 months. |
| Total Condomless Anal Sex Occurring in the Context of Insufficient PrEP Protection | Baseline, 6 month follow up, 12 month follow up. | Condomless anal sex acts not protected by PrEP, defined as condomless anal sex acts in the prior 6 months without protection via PrEP. We will measure sexual risk with the AIDS-Risk Behavior Assessment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Self-Reported PrEP Initiation | Baseline, 6 month follow up, 12 month follow up. | Self reported PrEP initiation variables will be measured for the purposes of characterizing the uptake of PrEP over the course of the study. We will use a self-reported approach to capture the date of initiation of medication, current use, and most recent date the medication was taken. |
Countries
United States
Contacts
CONTACTRebecca Schnall, PhD, MPH
PRINCIPAL_INVESTIGATORRebecca Schnall, PhD, MPH
Columbia University
PRINCIPAL_INVESTIGATORRobert Garofalo, MD, MPH
Ann & Robert H Lurie Children's Hospital of Chicago
PRINCIPAL_INVESTIGATORDustin Duncan, ScD
Columbia University
Outcome results
None listed